Filling the Treatment Gap: Geographic Expansion of Buprenorphine Providers Across the U.S.

From this analysis, it is evident that buprenorphine-certified providers are clustered in areas of higher drug-related mortality filling a treatment gap. The elimination of the X-waiver will be a significant step toward increasing access to medication for opioid use disorder, and this analysis may be used as a geographic baseline to assess in the future.